Formulation, evaluation, and in vitro drug diffusion of niosomal gel of selected drug

Abstract

Aim: To minimise toxicity and alter pharmacokinetic and bioavailability, niosomes are becoming more significant in medication delivery. Rheumatoid arthritis, juvenile rheumatoid arthritis, and degenerative joint disease may benefit from this new non-steroidal anti-inflammatory, antipyretic, and analgesic drug. Materials and Methods: Non-ionic surfactants (Span 40, 60, and Tween 60) and cholesterol were used in various ratios to create tolmetin sodium niosomes in a thin film hydration process (CHO). Evaluations of the formulations were conducted in terms of size, shape, encapsulation efficiency, and in vitro drug release. Results: In vitro drug release ranged from 94.87±0.45 to 93.19±0.45 percent in 24 hours for niosomes that looked spherical in entrapment efficiency. Incorporating Tolmetin sodium niosomes with Span 60 and CHO in the ratio of 1:2.1 into Carbopol gel was shown to be promising. Tolmetin drug noisome has a drug content and pH of 99.19±1.20 and 7.0±0.06, respectively. Conclusion: An improved bioavailability gel formulation with Tolmetin sodium in niosomal form demonstrated longer effect than gel formulations containing Tolmetin in non-niosomal form.